Wojtowicz Mariusz, Zdun Dariusz, Owczarek Aleksander J, Skrzypulec-Plinta Violetta, Olszanecka-Glinianowicz Magdalena
Clinical Department of Gynecology and Obstetrics Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice,, Poland.
Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland, Poland.
Ginekol Pol. 2025 May 26. doi: 10.5603/gpl.97117.
Some studies indicate the role of transforming growth factor-beta 1 (TGF-beta 1) in the development of endometriosis. However, the lack is studies assessed its plasma levels as a biomarker of endometrioma. Therefore, this study aimed to analyze plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations in women operated on for ovarian endometriosis.
A cross-sectional cohort study involved 56 women operated on for ovarian endometriosis. Body mass, height, and waist circumference were measured, as well as body mass index (BMI) being calculated. Plasma, peritoneal, and endometrioma fluid TGF-beta 1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Levels TGF-beta 1 were significantly higher in plasma than in both fluids (1286.1 pg/mL vs 114.7 pg/mL; p < 0.001 and 114.7 pg/mL vs 33.6 pg/mL; p < 0.001) and in endometrioma fluid than in peritoneal fluid (114.7 pg/mL vs 33.6 pg/mL; p < 0.001). There were also positive correlations between TGF-beta 1 levels in endometrioma and peritoneal fluids and plasma (r = 0.46; p < 0.001; r = 0.30; p < 0.05, respectively). There were no associations between TGF-beta 1 in plasma, endometrioma, peritoneal fluid, and endometriosis stage.
Our results suggest that plasma TGF-beta 1 concentration can be considered as a biomarker of endometrioma.
一些研究表明转化生长因子-β1（TGF-β1）在子宫内膜异位症的发展中起作用。然而，缺乏研究评估其血浆水平作为卵巢子宫内膜异位囊肿生物标志物的情况。因此，本研究旨在分析接受卵巢子宫内膜异位症手术的女性的血浆、腹膜液和卵巢子宫内膜异位囊肿液中的TGF-β1浓度。
一项横断面队列研究纳入了56例接受卵巢子宫内膜异位症手术的女性。测量了体重、身高和腰围，并计算了体重指数（BMI）。采用酶联免疫吸附测定（ELISA）法测定血浆、腹膜液和卵巢子宫内膜异位囊肿液中的TGF-β1浓度。
血浆中TGF-β1水平显著高于两种液体中的水平（分别为1286.1 pg/mL vs 114.7 pg/mL；p<0.001和114.7 pg/mL vs 33.6 pg/mL；p<0.001），且卵巢子宫内膜异位囊肿液中的TGF-β1水平高于腹膜液中的水平（114.7 pg/mL vs 33.6 pg/mL；p<0.001）。卵巢子宫内膜异位囊肿液和腹膜液与血浆中的TGF-β1水平之间也存在正相关（r = 0.46；p<0.001；r = 0.30；p<0.05）。血浆、卵巢子宫内膜异位囊肿、腹膜液中的TGF-β1与子宫内膜异位症分期之间无关联。
我们的结果表明血浆TGF-β1浓度可被视为卵巢子宫内膜异位囊肿的生物标志物。
